Burgess Global Consulting

• Drove services, reagents and licensing business development activities for publically traded stem cell company (www.stemcellsciences.com; London Exchange:  STEM)
• Founded nanotechnology-based cancer therapeutics company (www.nanomedinc.com)
• Restructured and streamlined research, development and manufacturing efforts at major nanotechnology company (www.zyvex.com)
• Led over 35 R&D and manufacturing scientists and engineers (www.zyvex.com)
• Scientific co-founder of publicly traded drug discovery company (www.lexpharma.com;  Nasdaq:  LEXG)
• Written eight bio- and nanotechnology-related patent applications and one book chapter
• Published scientific authorship in major peer-reviewed journals such as Science and Nature
• Expert in the fields of vertebrate functional genomics, stem cells and nanotechnology
• Specific emphasis on gene targeting and knockout technologies
• Extensive expertise in business and marketing plan formulation
• Over 100 direct upper-level business contacts in the stem cell, biotech and nanotech arenas

Dr. Burgess brings a strong Life Sciences background with a particular focus in molecular biology, in vivo drug target validation and genetic engineering to Burgess Global Consulting.  He recently held the position of Vice President, Business Development for the U.K.-based firm Stem Cell Sciences.  He was also Vice President, Research and Development for Zyvex Corporation where he guided a team of 36 scientists and research engineers and played an integral part in the company's restructuring.  Prior to Zyvex he was employed at Serologicals Corporation, a 1000 employee biotools and reagents company realizing $275M in 2005 revenue, as Director of Scientific Sourcing and New Technologies.  There he provided long-term visionary guidance for the company regarding new product and technology development opportunities through the establishment of key relationships and partnerships with academic researchers and institutions.  Prior to his appointment as Director of Scientific Sourcing and New Technologies he acted as Senior Director, Functional Genomics and Senior Director, Corporate Business Development for the Serologicals subsidiary Chemicon International.  In these capacities he managed a team of scientists focused on the generation of animal models for human disorders and identified and in-licensed new products and technologies from worldwide industrial and academic sources.

Dr. Burgess’ other roles in the biotechnology industry include Co-founder, Board Member and President of Genome BioSciences and Co-founding Scientist for Lexicon Genetics, where he focused on high-throughput drug target identification and validation at the molecular level.  In addition, as an NIH – sponsored Research Fellow he conducted research at the University of California – San Diego and has published in major scientific journals including Nature and Science on a variety of research in genetic engineering, developmental biology and the molecular control of cellular identity. 

Dr. Burgess holds a B.A. in biochemistry from the University of Texas at Austin and a Ph.D. in molecular biology from the University of Texas, M.D. Anderson Cancer Center in Houston.  He has received numerous awards including appointment to the Governor’s Blue Ribbon Steering Committee for the Southern California Life Sciences Summit and Visiting Scholar at Georgia Tech University. 

• Initiated and implemented the fluorescence polarization assay resulting in the efficient and timely characterization of key antibody/linker conjugates
• Designed and developed cell-based proteolytic-pathway assays in collaboration with corporate partners which were utilized to screen protease inhibitors targeting membrane-bound transcription factors
• Created and maintained cell bank databases and established core cell culture facility
• Performed extensive in vivo toxicology and efficacy studies of anti-cancer drug candidates
• 10+ years of industrial experience in drug discovery and development
• Extensive experience in target validation, assay development and formulating SOPs

• Grew company from zero life sciences revenue to $4 million in less than 4 years
• Won $3,200,000 U.S. Department of Defense contract for implantable wireless device for neuroprosthetics
• Won $210,000 NASA contract for development of space-based biological mass spectrometry.
• Introduced nanomanipulator for cell biology and tissue engineering, resulting in $400K in sales in 2 years
• Established spin-out of Medical Nanotechnologies, Inc. to develop nanomaterials for targeted therapy

• Professor, Departments of Molecular & Cell Biology and Chemistry, The University of Texas at Dallas
Expert in the filed of bionanotechnology as it applies to cell biology and cancer
Scientific focus on nanotoxicity and quantification of nanomaterials
• Associate Editor for the Bionanosciences Section of the journal “Experimental Biology and Medicine”
• Founder, UT Dallas Bionanosciences Group
• Former President, UT Dallas chapter of Texas Association of College Teachers
• Visiting Scholar, Stanford University, Stanford, California
• Recipient of two faculty development awards from UT Dallas